HTA / Market Access Launch Resources

To accelerate the launch of Olumiant AD and to make life easier for affiliates, GPORWE Intl is excited to introduce an interactive content Indirect hub to support HTA / Market Access strategy Comparison RELAYTO Life Sciences Solutions HTA / Market Access Goal Toolkits & Resources Go to Problem Goal Problem Solution Solution Demo Demo Feedback Feedback

BEYOND HTA/MARKET ACCESS Post-COVID-19 World Requires Better Digital Experience for… Payer, Healthcare Provider and Patient Post-COVID Essentials Higher focus on sophisticated digital engagement methods Standardized • to communicate complex scientific topics & build HTA/Market relationships Access New Brands • to launch new & complex products Launch & Indications • to play equal part in digital-F2F hybrid engagement Excellence Graham Lewis VP, Global Pharma Strategy, IQVIA May 2020 Patient Communications HTA Payer Single Brand Market Communications or Indication Healthcare Provider Communications Access Hub External Internal

IMPROVE outcomes, patient experience, clinician experience, payer experience, revenue per launch REDUCE total cost of care, time to launch, cost per launch Patient Outcomes & Market Access, Real World Evidence Pricing & Reimbursement Engage, communicate, and Time saved by Market Access / Price / collaborate effectively with customers Reimbursement team spent in and internal partners preparing Payer agreements Next Generation Contracting Model Increased bargaining power when Shared product knowledge, Speed, communicating value to Payers Improved coordination, will make life easier for affiliates and product teams

Improve... outcomes, patient experience, clinical experience, payer experience IMPROVE OUTCOMES RWE & RPA Mission & objectives Reduce: total cost of care, time to launch, cost per launch patient experience, clinical experience, payer experience REDUCE total cost of care, time to launch, cost per launch Patient Outcomes Market Access Real World Evidence Pricing & Reimbursement Deliver high quality, timely, and relevant Faster time to market will make life evidence to provide exceptional launch and better for patients and will support portfolio support profitable growth to invest in innovation Continue efforts to realize the full potential of Focus on execution real world evidence in clinical development and launch excellence $XXm price vs plan Increased productivity/time saved will be +$XXXm in volume due to early spent in high value RWE activities reimbursement vs plan

“I think we can do better than a PDF, it’s 2020” Publishing GVDs & HTA/Market Access toolkits is inefficient across tools/communication channels Off-Brand & Compliance AUGMENT Endless Files Conventional GVD difficult-to-navigate, localise, or understand Boring Lacks Context Fragmented ACCESS One-size-fits-all Global Value dissemination limits Difficult to Share/Secure Dossiers (GVD) affiliate adoption Paper-Optimized Market Access resources ANALYZE Lack of Insight

GVD / Folders IMPACT Fully-Branded Professionalism Off-Brand & Compliance Search & Navigation Save Time Endless Files Boring Interactive & Animated Understanding Lacks Context Context & Evidence Trust Organized Transparency Fragmented Reach Secure Sharing Difficult to Share/Secure Lack of Insight Code-free Paper-Optimized Any Devices Lack of Insight Engagement Insights Feedback & ROI

RELAYTO Workflow RELAYTO Workflow RELAYTO/ Document Experience ✓Fully branded ✓Persistent navigation & search 1. IMPORT 2. SHARE ✓Interactive & animated ✓500+ rich media embeds GVD Source Content RELAYTO/ Analytics ✓Real-time notifications 4. IMPROVE 3. ANALYZE ✓AI-powered optimisation ✓Engagement & conversions ✓Personalized recommendations

To accelerate the launch of Olumiant AD and to make life easier for affiliates, GPORWE Intl is excited to introduce an interactive content hub to support HTA / Market Access strategy DEMO Interactive Agenda HTA / Market Access Launch Resources Go to MAP HUB

To accelerate the launch of Olumiant AD and to make life easier for affiliates, GPORWE Intl is excited to introduce an interactive content hub to support HTA / Market Access strategy DEMO Interactive Toolkit Map HTA / Market Access Launch Resources Go to MAP HUB

DEMO Digital Life Sciences

USER BENEFIT Saves time & repurposes knowledge I really like the Interactive Hub. • One-stop-shop, where to find all relevant information for the submission (Pricing / Reimbursement / Access, Medical and Patient Outcomes / Real World Evidence). Good platform for sharing! • Many countries can benefit from what has been done to meet the needs of NICE, perfect to use that material for local adaptation. • Perfect to be able to share what evaluations that have been done for competitive brands in different markets. I believe this can save time and increase quality by collaborating using this platform. John Smith Pricing, Reimbursement and Market Access Sweden, UK Oncology

END-USER IMPACT Practical and adaptable to small markets I already checked the Hub and let me tell you it is absolutely great. • Appearance is very nice • Easy to navigate • Lots of presentations in one place • Practical I must tell that in our segment that we don’t have too much time to invest in new materials. The biggest challenge is always looking into the HTA site for the information we need for our specific purposes. This [RELAYTO] experience is easy to adapt, download and customize if it is necessary, if not just translate. John Smith Pricing, Reimbursement, Market Access | Colombia, LATAM

END-USER EXPERIENCE Superior to status quo like Sharepoint I think it is much clearer than the classic SharePoint page and you have a quicker overview of what is available and where documents are located. It is easier to handle than the folder structure of the SharePoint page. Also, the [RELAYTO] page simply looks more lively and very beautiful, so it's more fun to work with. John Smith Health Economics, Medical Affairs, Germany

LEADERSHIP SUPPORT Efficiency and ease of use across affiliates Great work – this should greatly improve the efficiency for our affiliate John Smith, MSEd partners as we prepare for [ ] launch. I appreciate you bringing this Global Pricing Reimbursement and Access innovative new approach to our global [ ] community Indianapolis It’s easy and intuitive to use. Would love to add region specific info too. John Smith PhD HTA Scientific Leader, Latin America Eli Lilly Toronto I think the tool looks very good and feels super user-friendly. I really like the fact that everything is collected in one single place. For us it is also important that we can download some of the material and John Smith Franco, MSc. happy to see that function easily accessible as well. PRA (Price, Reimbursement and Access) Manager Sweden

BEYOND Unsolicited interest in expanding across I would like to implement this platform for other indications also! John Smith The interactive platform is a great idea. Health Economics, Medical Affairs, Germany If the idea is to do the same [experience] for the other brands let John Smith me tell you, it's a fantastic idea. Pricing, Reimbursement, Market Access | Colombia, LATAM I would very much like this platform to be developed for other brands. John Smith Pricing, Reimbursement and Market Access ,Sweden, UK Oncology

Patient Outcomes Real World Evidence Deliver high quality, timely, and relevant evidence to FOCUS ON EXECUTION AND provide exceptional launch and portfolio support LAUNCH EXCELLENCE Continue efforts to realize the full potential of real world evidence in clinical development Increased productivity/time saved will be spent IMPROVE OUTCOMES in high value RWE activities • Patient experience • Clinical experience Market Access • Payer experience Pricing & Reimbursement Faster time to market will make life better for patients and will support profitable growth to invest in innovation REDUCE • Total cost of care $XXm price vs plan • Time to launch +$XXXm in volume due to early reimbursement vs plan • Cost per launch

HTA / Market Access Strategy Toolkit MAP Value Story & RWE Insight Objection Negotiations & HTA/Payer Pricing Evidence Based Generation/ Handler Strategy HTA/Payer Decision Maker Messages Patient Needs Questions Understanding Support DSP Data Disease State Objection Cost-effectiven Payer Appraisals Resource Handler ess Model Response Hub UK Country Treatment FAQ Reports Protocol GER Core Value IT FDA Message Budget Impact Pediatrics Adjusted NICE Global Payer Comparison Patient Dossier HAS Preference Study TLV HTA Toolkit Patient GBA Testimonials Indirect Local ICER Comparison Clinical Study customizations All content is for Lilly HTA/PAYER engagement/submissions HTA/≠PAYER negotiations internal use only & is regularly updated until market authorizations LOCAL CUSTOMIZATIONS | HTA/PAYER ENGAGEMENT